Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-13 |
2024-09 |
-0.16 |
N/A |
N/A |
N/A |
2024-08-01 |
2024-06 |
-0.18 |
-0.17 |
0.01 |
5.56% |
2024-05-02 |
2024-03 |
-0.18 |
-0.2 |
-0.02 |
-11.11% |
2024-03-11 |
2023-12 |
-0.23 |
-0.2 |
0.03 |
13.04% |
2023-11-08 |
2023-09 |
-0.22 |
-0.21 |
0.01 |
4.55% |
2023-08-03 |
2023-06 |
-0.17 |
-0.22 |
-0.05 |
-29.41% |
Date |
Firm |
Action |
From |
To |
2023-05-30 |
Citigroup |
Upgrade |
Buy |
Buy |
2023-05-29 |
Needham |
Upgrade |
|
Hold |
2023-03-06 |
Jefferies |
Upgrade |
|
Hold |
2022-11-21 |
Citigroup |
Upgrade |
Buy |
Buy |
2022-08-11 |
Piper Sandler |
Upgrade |
|
Overweight |
2022-06-30 |
Citigroup |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-04-25 |
AMOUYAL PHILIPPE |
Director |
248.36K |
Conversion of Exercise of derivative security |
2024-05-09 |
ARTAL INTERNATIONAL S.C.A. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2024-04-25 |
BARKER SAMUEL L |
Director |
87.65K |
Conversion of Exercise of derivative security |
2024-02-27 |
COATS LONNEL |
Chief Executive Officer |
1.10M |
Conversion of Exercise of derivative security |
2024-04-25 |
DEBBANE RAYMOND |
Director |
6.80M |
Conversion of Exercise of derivative security |
2024-04-25 |
LEFKOWITZ ROBERT J |
Director |
48.36K |
Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Artal Group S.A. |
117.55M |
269.20M |
48.00% |
2023-06-29 |
BVF Inc. |
20.00M |
45.79M |
8.16% |
2023-06-29 |
FMR, LLC |
8.51M |
19.49M |
3.47% |
2023-06-29 |
Vanguard Group Inc |
6.46M |
14.79M |
2.64% |
2023-06-29 |
Blackrock Inc. |
6.38M |
14.61M |
2.60% |
2023-06-29 |
JP Morgan Chase & Company |
2.93M |
6.71M |
1.20% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.70M |
8.48M |
1.51% |
2023-08-30 |
Fidelity Growth Company Fund |
2.53M |
4.35M |
1.03% |
2023-08-30 |
iShares Russell 2000 ETF |
2.15M |
3.69M |
0.88% |
2023-06-29 |
JP Morgan Small Cap Value Fund |
1.43M |
3.27M |
0.58% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.42M |
3.25M |
0.58% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
1.09M |
1.87M |
0.44% |
Split |
Date |
1 : 7 |
2015-05-21 |